In this episode of Ideas to Innovation, Clarivate life sciences and healthcare experts reflect on partnering with pharma to combat the pandemic. Listen now.
COVID-19 has presented an enormous global challenge, requiring an unprecedented level of engagement by stakeholders across pharma, research and policy. While SARS-CoV-2 emerged as a novel virus to which humans had no immunity, infection control measures have now been deployed and existing, new and emerging technologies are helping to speed the development of new treatments and therapies.
To aid in this effort, Clarivate partnered with pharma companies in an international effort to bring life-saving vaccines to market. From developing medical dashboards and automated analyses to conducting in-depth trademark research, they pushed boundaries to develop the best solutions using our data, technology and expertise.
In this new episode of our Ideas to Innovation podcast series, Clarivate experts provide a snapshot of their key milestones over the past year and share their perspectives on what may come next. At this session, we feature:
- Danielle Waterman, Senior Quality Specialist, Clarivate,
- Lynn Yoffee, Publisher BioWorld™, Clarivate, and
- Kevin Yin, Senior Analyst – Medtech Insights, Clarivate.
Listen in as they discuss key medical responses to the pandemic, what the “new normal” looks like and review the latest data and insights that can provide a complete view of the healthcare landscape.
United by a common cause, a global team of Clarivate experts partnered with pharmaceutical companies to fight COVID-19. The reward for their ingenuity: Life-saving vaccines brought to market in record time. Get the full story.